Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
4.100
-0.330 (-7.45%)
At close: Jan 29, 2026, 4:00 PM EST
4.100
0.00 (0.00%)
After-hours: Jan 29, 2026, 8:00 PM EST
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2024. The number of employees decreased by 3 or -37.50% compared to the previous year.
Employees
5
Change (1Y)
-3
Growth (1Y)
-37.50%
Revenue / Employee
$112,000
Profits / Employee
-$1,759,800
Market Cap
5.94M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Sep 30, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | 8 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BiomX | 57 |
| Abpro Holdings | 15 |
| Genprex | 15 |
| Aprea Therapeutics | 8 |
| Indaptus Therapeutics | 7 |
| Adial Pharmaceuticals | 5 |
| 60 Degrees Pharmaceuticals | 3 |
| Xenetic Biosciences | 2 |
CANF News
- 5 weeks ago - Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - GlobeNewsWire
- 6 weeks ago - Can-Fite Provides Update on Clinical and Financial Status - GlobeNewsWire
- 2 months ago - Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - GlobeNewsWire
- 5 months ago - Can-Fite Reports H1 2025 Financial Results and Clinical Update - GlobeNewsWire
- 6 months ago - Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone - GlobeNewsWire
- 6 months ago - Can-Fite Announces Up To $15.0 Million Public Offering - GlobeNewsWire
- 6 months ago - Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia - GlobeNewsWire
- 10 months ago - Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients - GlobeNewsWire